INmune Bio Inc. (NASDAQ: INMB) — Company Snapshot (as of ~Oct 31, 2026)

INmune Bio is a pre-revenue, clinical-stage immunology/biotechnology company headquartered in Boca Raton, Florida, developing therapies that target the innate immune system for diseases such as Alzheimer's, cancer, and immune-mediated conditions [11], [20]. It trades on Nasdaq under INMB. As of Oct 30, 2026 the stock closed at ~$1.45 (down 9.38% that day), with a market cap of ~$44.4–44.9M, a 52-week range of $1.09–$2.60, and total cash of ~$18.4M [8], [9], [19].

---

Recent Catalysts (roughly Aug–Oct 2026)